Here are the 10-Q quarterly reports from Celularity Inc. Warrant (CELUW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CELUW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELUW filings page.
Celularity Inc. reported unaudited interim financials showing a wide operating deficit and continued liquidity pressure. The company had an accumulated deficit of $944,025 and total current assets of $17,263 versus total current liabilities of $69,227, indicating current liabilities materially exceed short-term resources. The filing discloses substantial outstanding debt subject to forbearance agreements, and management states the company expects to continue incurring significant operating losses and using net cash for operations. Warrant liabilities rose to $8,780 from $3,264, and the company recorded losses on debt extinguishment (including $5,736) during the six months ended June 30, 2025. Material financing and restructuring activities noted include PIPE and registered-direct financings (e.g., $6,000 January 2024 PIPE) and planned asset transactions (Asset Purchase Agreement for $33,812) to address indebtedness.
Celularity, Inc. reported interim results in a Form 10-Q for the quarter ended March 31, 2025. The company had $22,080 of current assets and $58,690 of current liabilities, reflecting a working capital deficit. Total long-term related‑party debt was $36,492 and warrant liabilities increased to $8,067 as of March 31, 2025. Accumulated deficit was $919,501. Net revenues from services were $1,408 for the quarter, up 9.4% from $1,287 year‑over‑year, while loss before income taxes narrowed to $(19,754) from $(22,013). The filing discloses multiple debt facilities, forbearance arrangements and convertible note terms, material warrant and contingent consideration balances, and ongoing litigation and settlement items. The company states it expects to continue incurring operating losses and using cash for operations.